Obesity drug competition expected to intensify by 2030
Drug Discovery World
AUGUST 2, 2024
Assuming VK2735 enters Phase III clinical trials next year, it could become one of the next therapies to enter the market, directly competing with Eli Lilly’s tirzepatide due to its similar mechanism of action.” The promising results could give VK2735 a competitive edge over other candidates in the pipeline.
Let's personalize your content